metformin has been researched along with Diabetic Neuropathies in 52 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thus far, the treatment of painful diabetic neuropathy remains unsatisfactory." | 5.42 | Metformin attenuates hyperalgesia and allodynia in rats with painful diabetic neuropathy induced by streptozotocin. ( Chen, Y; Liu, J; Ma, J; Wang, Q; Xiang, L; Yu, H, 2015) |
| " The prevalence of gastroparesis symptoms is 6% and is independently related to metformin use, and therefore, symptomatic screening is required to decide which patients need further evaluation." | 3.88 | Prevalence of cardiovascular autonomic neuropathy and gastroparesis symptoms among patients with type 2 diabetes who attend a primary health care center. ( AlHarbi, TJ; AlOlaiwi, LA; Tourkmani, AM, 2018) |
| "In participants with type 2 diabetes, the incidences of microvascular complications and death were not materially different among the four treatment groups." | 3.11 | Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. ( Bebu, I; Burch, HB; Buse, JB; Cherrington, AL; Fortmann, SP; Green, JB; Kahn, SE; Kirkman, MS; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Phillips, LS; Pop-Busui, R; Steffes, M; Tiktin, M; Tripputi, M; Wexler, DJ; Younes, N, 2022) |
| "Metformin treatment did not affect VDT group difference - 0." | 2.94 | Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial. ( Almdal, T; Carstensen, B; Gluud, C; Hansen, CS; Hedetoft, C; Hemmingsen, B; Jørgensen, ME; Krarup, T; Lund, SS; Lundby-Christiansen, L; Madsbad, S; Sneppen, SB; Tarnow, L; Thorsteinsson, B; Wiinberg, N, 2020) |
| "Metformin is a hypoglycemic drug widely used in the treatment of type 2 diabetes." | 2.82 | Is metformin a possible treatment for diabetic neuropathy? ( Huang, M; Jia, S; Wang, P; Wei, J; Wei, Y, 2022) |
| "Metformin is a potent antihyperglycemic agent widely used in the management of type 2 diabetes whose main actions are the suppression of gluconeogenesis and the improvement of glucose uptake and insulin sensitivity." | 2.44 | Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. ( Carvalho, C; Correia, S; Moreira, PI; Oliveira, CR; Santos, MS; Seiça, R, 2008) |
| "Metformin treatment was defined as any record of metformin prescription." | 1.91 | Metformin treatment and risk of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus in Beijing, China. ( Chen, H; Hu, Y; Qin, X; Wang, M; Wang, S; Wu, J; Wu, T; Wu, Y; Yang, R; Yu, H, 2023) |
| " Three days of cumulative dosing were administered to establish morphine tolerance in rats." | 1.72 | Metformin prevents morphine-induced apoptosis in rats with diabetic neuropathy: a possible mechanism for attenuating morphine tolerance. ( Avci, O; Gursoy, S; Inan, ZDS; Ozdemir, E; Taskiran, AS, 2022) |
| "Neuropathic pain is a common complication of diabetes mellitus with poorly relieved by conventional analgesics." | 1.62 | Metformin attenuates diabetic neuropathic pain via AMPK/NF-κB signaling pathway in dorsal root ganglion of diabetic rats. ( Cao, XJ; Chen, X; Qian, HY; Sun, YZ; Wu, R; Xu, GY; Zhang, PA; Zhu, HY, 2021) |
| "Metformin-treated diabetics (MTD) showed a decrease in cobalamin, a rise in homocysteine, and methylmalonic acid, leading to accentuated diabetic peripheral neuropathy (DPN)." | 1.62 | The relationship between exacerbated diabetic peripheral neuropathy and metformin treatment in type 2 diabetes mellitus. ( El-Sherif, M; Esmael, A; Hashem, MM; Nassar, AK, 2021) |
| "Our results indicate that painful diabetic neuropathy is associated with a serial of morphometric plasticity in the rat spinal cord including the numerical increase of the myelinated fibers in the spinothalamic tract and the oligodendrocytes in the spinal dorsal horn." | 1.56 | Stereological study on the numerical plasticity of myelinated fibers and oligodendrocytes in the rat spinal cord with painful diabetic neuropathy. ( He, YN; Lin, JY; Peng, B; Xu, BL; Zhu, N, 2020) |
| "Metformin has beneficial pharmacological effects on the preservation of peripheral nerves in diabetic rats and its effects are comparable to those of ALA." | 1.56 | Metformin Preserves Peripheral Nerve Damage with Comparable Effects to Alpha Lipoic Acid in Streptozotocin/High-Fat Diet Induced Diabetic Rats. ( Jin, HY; Kim, SH; Park, TS, 2020) |
| "Vitamin B12 deficiency was recorded at ≤187 pg/ml." | 1.51 | Vitamin B12 status and peripheral neuropathy in patients with type 2 diabetes mellitus. ( Ashor, AW; Khalaf, KM; Khudhair, MS, 2019) |
| "Von Frey filaments were used to assess tactile allodynia." | 1.48 | Evaluation of the neonatal streptozotocin model of diabetes in rats: Evidence for a model of neuropathic pain. ( Barragán-Iglesias, P; Delgado-Lezama, R; Granados-Soto, V; Hong, E; Loeza-Alcocer, E; Oidor-Chan, VH; Pineda-Farias, JB; Price, TJ; Salinas-Abarca, AB; Sánchez-Mendoza, A; Velazquez-Lagunas, I, 2018) |
| "Metformin treatment increased the number of structural defects of the myelin sheet surrounding these fibers in already affected nerves of HFD fed mice, and simvastatin treatment reduced these numbers to the levels seen in control mice." | 1.48 | Metformin exacerbates and simvastatin attenuates myelin damage in high fat diet-fed C57BL/6 J mice. ( Bumbasirevic, V; Ciric, D; Kravic-Stevovic, T; Martinovic, T; Petricevic, S; Trajkovic, V, 2018) |
| "469 ambulatory type 2 diabetes patients (mean diabetes duration 10." | 1.46 | Vitamin B12 deficiency is associated with cardiovascular autonomic neuropathy in patients with type 2 diabetes. ( Fleischer, J; Hansen, CS; Jensen, JS; Jørgensen, ME; Ridderstråle, M; Vistisen, D, 2017) |
| "Metformin-treated subjects (n = 124, 47 %) showed significantly lower levels of vitamin B12 (P < 0." | 1.43 | Diabetic neuropathy is not associated with homocysteine, folate, vitamin B12 levels, and MTHFR C677T mutation in type 2 diabetic outpatients taking metformin. ( Alibrandi, A; Cucinotta, D; Forte, F; Gambadoro, N; Giandalia, A; Perdichizzi, G; Romeo, EL; Russo, GT; Scarcella, C; Zingale, R, 2016) |
| "The included 3810 patients with type 2 diabetes had their treatment intensified at baseline." | 1.43 | Incidence, characteristics and impact of hypoglycaemia in patients receiving intensified treatment for inadequately controlled type 2 diabetes mellitus. ( Bramlage, P; Gitt, AK; Schneider, S; Tschöpe, D, 2016) |
| "In an observational study, among 550 type 2 diabetes patients using metformin, cobalamin and holotranscobalamin (holoTCII) levels were measured at the annual diabetes checkup, and deficiencies were defined as <148 and <21 pmol/L, respectively." | 1.42 | Cobalamin status and its relation with depression, cognition and neuropathy in patients with type 2 diabetes mellitus using metformin. ( Beulens, JW; Biemans, E; Cuellar Renteria, VG; Hart, HE; Kooijman-Buiting, AM; Rutten, GE, 2015) |
| "Chronic pain is a common complication of diabetes." | 1.42 | Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments. ( Byrne, FM; Chapman, V; Cheetham, S; Vickers, S, 2015) |
| "Thus far, the treatment of painful diabetic neuropathy remains unsatisfactory." | 1.42 | Metformin attenuates hyperalgesia and allodynia in rats with painful diabetic neuropathy induced by streptozotocin. ( Chen, Y; Liu, J; Ma, J; Wang, Q; Xiang, L; Yu, H, 2015) |
| "Metformin-treated patients had depressed Cbl levels and elevated fasting MMA and Hcy levels." | 1.36 | Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. ( Toth, C; Wile, DJ, 2010) |
| "A total of 2,368 patients with type 2 diabetes and CAD was evaluated." | 1.35 | Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. ( Jones, TL; Lopes, N; Lu, J; Pop-Busui, R, 2009) |
| "Insulin sensitivity was measured using the insulin tolerance test (ITT), both in STZ diabetic and in Zucker diabetic fatty (ZDF) rats (model of type 2 diabetes)." | 1.31 | Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models. ( Bíró, K; Jednákovits, A; Kukorelli, T; Kürthy, M; Mogyorósi, T; Nagy, K; Tálosi, L, 2002) |
| "Chronic diarrhea is more frequent in type I diabetic patients." | 1.30 | The prevalence of chronic diarrhea among diabetic patients. ( Goldin, E; Israeli, E; Lysy, J, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (11.54) | 18.2507 |
| 2000's | 7 (13.46) | 29.6817 |
| 2010's | 22 (42.31) | 24.3611 |
| 2020's | 17 (32.69) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, XJ | 1 |
| Wu, R | 1 |
| Qian, HY | 1 |
| Chen, X | 1 |
| Zhu, HY | 1 |
| Xu, GY | 1 |
| Sun, YZ | 1 |
| Zhang, PA | 1 |
| Haddad, M | 1 |
| Eid, S | 1 |
| Harb, F | 1 |
| Massry, MEL | 1 |
| Azar, S | 1 |
| Sauleau, EA | 1 |
| Eid, AA | 1 |
| Avci, O | 1 |
| Ozdemir, E | 1 |
| Taskiran, AS | 1 |
| Inan, ZDS | 1 |
| Gursoy, S | 1 |
| Wei, J | 1 |
| Wei, Y | 1 |
| Huang, M | 1 |
| Wang, P | 1 |
| Jia, S | 1 |
| Nathan, DM | 1 |
| Lachin, JM | 1 |
| Bebu, I | 1 |
| Burch, HB | 1 |
| Buse, JB | 2 |
| Cherrington, AL | 1 |
| Fortmann, SP | 1 |
| Green, JB | 2 |
| Kahn, SE | 1 |
| Kirkman, MS | 1 |
| Krause-Steinrauf, H | 1 |
| Larkin, ME | 1 |
| Phillips, LS | 2 |
| Pop-Busui, R | 2 |
| Steffes, M | 1 |
| Tiktin, M | 1 |
| Tripputi, M | 1 |
| Wexler, DJ | 1 |
| Younes, N | 1 |
| Xu, C | 1 |
| Wang, F | 1 |
| Su, C | 1 |
| Guo, X | 1 |
| Li, J | 1 |
| Lin, J | 1 |
| Yang, R | 1 |
| Yu, H | 2 |
| Wu, J | 1 |
| Chen, H | 1 |
| Wang, M | 1 |
| Wang, S | 1 |
| Qin, X | 1 |
| Wu, T | 1 |
| Wu, Y | 1 |
| Hu, Y | 1 |
| Jin, HY | 2 |
| Lee, KA | 1 |
| Kim, YJ | 1 |
| Gwak, IS | 1 |
| Park, TS | 2 |
| Yeom, SW | 1 |
| Kim, JS | 1 |
| Kempler, P | 1 |
| Menyhárt, A | 1 |
| Horváth, V | 1 |
| Kiss, ÁT | 1 |
| Körei, AE | 1 |
| Pușcașu, C | 1 |
| Ungurianu, A | 1 |
| Șeremet, OC | 1 |
| Andrei, C | 1 |
| Mihai, DP | 1 |
| Negreș, S | 1 |
| Khalaf, KM | 1 |
| Khudhair, MS | 1 |
| Ashor, AW | 1 |
| Lin, JY | 2 |
| Zhu, N | 2 |
| He, YN | 2 |
| Xu, BL | 1 |
| Peng, B | 2 |
| Gabriel, R | 1 |
| Boukichou Abdelkader, N | 1 |
| Acosta, T | 1 |
| Gilis-Januszewska, A | 1 |
| Gómez-Huelgas, R | 1 |
| Makrilakis, K | 1 |
| Kamenov, Z | 1 |
| Paulweber, B | 1 |
| Satman, I | 1 |
| Djordjevic, P | 1 |
| Alkandari, A | 1 |
| Mitrakou, A | 1 |
| Lalic, N | 1 |
| Colagiuri, S | 1 |
| Lindström, J | 1 |
| Egido, J | 1 |
| Natali, A | 1 |
| Pastor, JC | 1 |
| Teuschl, Y | 1 |
| Lind, M | 1 |
| Silva, L | 1 |
| López-Ridaura, R | 1 |
| Tuomilehto, J | 1 |
| Kim, SH | 1 |
| Hansen, CS | 2 |
| Lundby-Christiansen, L | 1 |
| Tarnow, L | 1 |
| Gluud, C | 1 |
| Hedetoft, C | 1 |
| Thorsteinsson, B | 1 |
| Hemmingsen, B | 1 |
| Wiinberg, N | 1 |
| Sneppen, SB | 1 |
| Lund, SS | 1 |
| Krarup, T | 1 |
| Madsbad, S | 1 |
| Almdal, T | 1 |
| Carstensen, B | 1 |
| Jørgensen, ME | 2 |
| Serra, MC | 1 |
| Kancherla, V | 1 |
| Khakharia, A | 1 |
| Allen, LL | 1 |
| Rhee, MK | 1 |
| Wilson, PWF | 1 |
| Vaughan, CP | 1 |
| Hashem, MM | 1 |
| Esmael, A | 1 |
| Nassar, AK | 1 |
| El-Sherif, M | 1 |
| Xing, L | 1 |
| Peng, F | 1 |
| Liang, Q | 1 |
| Dai, X | 1 |
| Ren, J | 1 |
| Wu, H | 1 |
| Yang, S | 1 |
| Zhu, Y | 1 |
| Jia, L | 1 |
| Zhao, S | 1 |
| Barragán-Iglesias, P | 1 |
| Oidor-Chan, VH | 1 |
| Loeza-Alcocer, E | 1 |
| Pineda-Farias, JB | 1 |
| Velazquez-Lagunas, I | 1 |
| Salinas-Abarca, AB | 1 |
| Hong, E | 1 |
| Sánchez-Mendoza, A | 1 |
| Delgado-Lezama, R | 1 |
| Price, TJ | 1 |
| Granados-Soto, V | 1 |
| Al-Assi, O | 1 |
| Ghali, R | 1 |
| Mroueh, A | 1 |
| Kaplan, A | 1 |
| Mougharbil, N | 1 |
| Eid, AH | 1 |
| Zouein, FA | 1 |
| El-Yazbi, AF | 1 |
| Ciric, D | 1 |
| Martinovic, T | 1 |
| Petricevic, S | 1 |
| Trajkovic, V | 1 |
| Bumbasirevic, V | 1 |
| Kravic-Stevovic, T | 1 |
| AlOlaiwi, LA | 1 |
| AlHarbi, TJ | 1 |
| Tourkmani, AM | 1 |
| Lós, DB | 1 |
| Oliveira, WH | 1 |
| Duarte-Silva, E | 1 |
| Sougey, WWD | 1 |
| Freitas, EDSR | 1 |
| de Oliveira, AGV | 1 |
| Braga, CF | 1 |
| França, MER | 1 |
| Araújo, SMDR | 1 |
| Rodrigues, GB | 1 |
| Rocha, SWS | 1 |
| Peixoto, CA | 1 |
| Moraes, SRA | 1 |
| Biemans, E | 1 |
| Hart, HE | 1 |
| Rutten, GE | 1 |
| Cuellar Renteria, VG | 1 |
| Kooijman-Buiting, AM | 1 |
| Beulens, JW | 1 |
| Byrne, FM | 1 |
| Cheetham, S | 1 |
| Vickers, S | 1 |
| Chapman, V | 1 |
| Alamdari, A | 1 |
| Mozafari, R | 1 |
| Tafakhori, A | 1 |
| Faghihi-Kashani, S | 1 |
| Hafezi-Nejad, N | 1 |
| Sheikhbahaei, S | 1 |
| Naderi, N | 1 |
| Ebadi, M | 1 |
| Esteghamati, A | 1 |
| Ma, J | 1 |
| Liu, J | 1 |
| Chen, Y | 1 |
| Wang, Q | 1 |
| Xiang, L | 1 |
| Russo, GT | 1 |
| Giandalia, A | 1 |
| Romeo, EL | 1 |
| Scarcella, C | 1 |
| Gambadoro, N | 1 |
| Zingale, R | 1 |
| Forte, F | 1 |
| Perdichizzi, G | 1 |
| Alibrandi, A | 1 |
| Cucinotta, D | 1 |
| Tschöpe, D | 1 |
| Bramlage, P | 1 |
| Schneider, S | 1 |
| Gitt, AK | 1 |
| Hasanvand, A | 1 |
| Amini-Khoei, H | 1 |
| Hadian, MR | 1 |
| Abdollahi, A | 1 |
| Tavangar, SM | 1 |
| Dehpour, AR | 1 |
| Semiei, E | 1 |
| Mehr, SE | 1 |
| Josse, RG | 1 |
| Majumdar, SR | 1 |
| Zheng, Y | 1 |
| Adler, A | 1 |
| Bethel, MA | 1 |
| Kaufman, KD | 1 |
| Rodbard, HW | 1 |
| Tankova, T | 1 |
| Westerhout, CM | 1 |
| Peterson, ED | 1 |
| Holman, RR | 2 |
| Armstrong, PW | 1 |
| Jensen, JS | 1 |
| Ridderstråle, M | 1 |
| Vistisen, D | 1 |
| Fleischer, J | 1 |
| Jiménez-Ramírez, FJ | 1 |
| Castro, LM | 1 |
| Ortiz, C | 1 |
| Concepción, J | 1 |
| Renta, JY | 1 |
| Morales-Borges, RH | 1 |
| Miranda-Massari, JR | 2 |
| Duconge, J | 2 |
| Pishdad, GR | 1 |
| Pishdad, P | 1 |
| Pishdad, R | 1 |
| Correia, S | 1 |
| Carvalho, C | 1 |
| Santos, MS | 1 |
| Seiça, R | 1 |
| Oliveira, CR | 1 |
| Moreira, PI | 1 |
| Duckworth, W | 1 |
| Abraira, C | 1 |
| Moritz, T | 1 |
| Reda, D | 1 |
| Emanuele, N | 1 |
| Reaven, PD | 1 |
| Zieve, FJ | 1 |
| Marks, J | 1 |
| Davis, SN | 1 |
| Hayward, R | 1 |
| Warren, SR | 1 |
| Goldman, S | 1 |
| McCarren, M | 1 |
| Vitek, ME | 1 |
| Henderson, WG | 1 |
| Huang, GD | 1 |
| Lu, J | 1 |
| Lopes, N | 1 |
| Jones, TL | 1 |
| Wile, DJ | 1 |
| Toth, C | 1 |
| Gonzalez, MJ | 1 |
| Jimenez, FJ | 1 |
| Allende-Vigo, MZ | 1 |
| Kuritzky, L | 1 |
| Pierce, SA | 1 |
| Chung, AH | 1 |
| Black, KK | 1 |
| El-Mir, MY | 1 |
| Detaille, D | 1 |
| R-Villanueva, G | 1 |
| Delgado-Esteban, M | 1 |
| Guigas, B | 1 |
| Attia, S | 1 |
| Fontaine, E | 1 |
| Almeida, A | 1 |
| Leverve, X | 1 |
| Zhang, YF | 1 |
| Ning, G | 1 |
| Turner, RC | 1 |
| Rubenstein, AH | 1 |
| Waterman, PE | 1 |
| Lysy, J | 1 |
| Israeli, E | 1 |
| Goldin, E | 1 |
| Holstein, A | 1 |
| Nahrwold, D | 1 |
| Hinze, S | 1 |
| Egberts, EH | 1 |
| Buysschaert, M | 1 |
| Hermans, MP | 1 |
| Kürthy, M | 1 |
| Mogyorósi, T | 1 |
| Nagy, K | 1 |
| Kukorelli, T | 1 |
| Jednákovits, A | 1 |
| Tálosi, L | 1 |
| Bíró, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study[NCT01794143] | Phase 3 | 5,047 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Early Prevention of Diabetes Complications in People With Hyperglycaemia in Europe: e-PREDICE Study[NCT03222765] | 1,000 participants (Anticipated) | Interventional | 2015-03-15 | Recruiting | |||
| The Effect of Metformin Versus Placebo, Including Three Insulin-Analogue Regimens With Variating Postprandial Glucose Regulation, on CIMT in T2DM Patients - A Randomized, Multicenter Trial[NCT00657943] | Phase 4 | 415 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)[NCT00032487] | Phase 3 | 1,791 participants (Actual) | Interventional | 2000-12-01 | Completed | ||
| Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes[NCT00006305] | Phase 3 | 2,368 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| The Impact of Glucose Lowering Therapies Including Dipeptidyl Peptidase-4 Inhibitor on Circulating Endothelial Progenitor Cells (EPCs) and Its Mobilising Factor Stromal Derived Factor-1α (SDF-1α) in Patients With Type 2 Diabetes[NCT02694575] | 241 participants (Actual) | Observational | 2015-03-01 | Completed | |||
| A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)[NCT00244244] | Phase 2 | 80 participants | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Myocardial infarction (MI), intervention for coronary artery or Peripheral Vascular Disease (PVD), severe inoperable Coronary Artery Disease (CAD), new or worsening Congestive Heart Failure (CHF), stroke, Cardiovascular (CV) death, or amputation for ischemic gangrene. (NCT00032487)
Timeframe: Post baseline time to the first major macrovascular event up to 82 months
| Intervention | participants (Number) |
|---|---|
| Arm 1 | 264 |
| Arm 2 | 235 |
New or worsening angina, new transient ischemic attack (TIA), new intermittent claudication or critical limb ischemia with Doppler evidence or total mortality. (NCT00032487)
Timeframe: Post baseline time to first event up to 82 months
| Intervention | participants (Number) |
|---|---|
| Arm 1 | 283 |
| Arm 2 | 312 |
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
(NCT00006305)
Timeframe: five years
| Intervention | participants (Number) |
|---|---|
| Revascularization and Insulin Providing (IP) | 80 |
| Revascularization and Insulin Sensitizing (IS) | 75 |
| Medical Therapy and Insulin Providing (IP) | 80 |
| Medical Therapy and Insulin Sensitizing (IS) | 81 |
(NCT00006305)
Timeframe: five years
| Intervention | participants (Number) |
|---|---|
| Revascularization and Insulin Providing (IP) | 145 |
| Revascularization and Insulin Sensitizing (IS) | 121 |
| Medical Therapy and Insulin Providing (IP) | 143 |
| Medical Therapy and Insulin Sensitizing (IS) | 140 |
5 reviews available for metformin and Diabetic Neuropathies
| Article | Year |
|---|---|
Is metformin a possible treatment for diabetic neuropathy?
Topics: Adenosine Monophosphate; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Hypoglycemic Agen | 2022 |
Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neuropat | 2008 |
Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dietary Supplements; Disease Progre | 2011 |
Mecobalamin.
Topics: Aged; Alprostadil; Animals; Cobamides; Coenzymes; Diabetic Neuropathies; Drug Administration Routes; | 2008 |
Lessons from UK prospective diabetes study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Foot; Diabeti | 1995 |
6 trials available for metformin and Diabetic Neuropathies
| Article | Year |
|---|---|
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
Topics: Albuminuria; Blood Glucose; Cardiovascular Diseases; Comparative Effectiveness Research; Diabetes Co | 2022 |
Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data.
Topics: Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathi | 2020 |
Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial.
Topics: Aged; Autonomic Nervous System Diseases; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Neuropa | 2020 |
Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
Topics: Age Factors; Aged; Blood Preservation; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blin | 2017 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Lessons from UK prospective diabetes study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Foot; Diabeti | 1995 |
42 other studies available for metformin and Diabetic Neuropathies
| Article | Year |
|---|---|
Metformin attenuates diabetic neuropathic pain via AMPK/NF-κB signaling pathway in dorsal root ganglion of diabetic rats.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Experimental; | 2021 |
Activation of 20-HETE Synthase Triggers Oxidative Injury and Peripheral Nerve Damage in Type 2 Diabetic Mice.
Topics: AMP-Activated Protein Kinases; Animals; Cytochrome P-450 CYP4A; Diabetes Mellitus, Experimental; Dia | 2022 |
Metformin prevents morphine-induced apoptosis in rats with diabetic neuropathy: a possible mechanism for attenuating morphine tolerance.
Topics: Analgesics; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Diabetes Mellitus, Experiment | 2022 |
Restoration of aquaporin-4 polarization in the spinal glymphatic system by metformin in rats with painful diabetic neuropathy.
Topics: Animals; Aquaporin 4; Contrast Media; Diabetes Mellitus; Diabetic Neuropathies; Glymphatic System; M | 2023 |
Metformin treatment and risk of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus in Beijing, China.
Topics: Beijing; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Metformin; Middle Aged; Vitamin B | 2023 |
Bidirectional association between diabetic peripheral neuropathy and vitamin B12 deficiency: Two longitudinal 9-year follow-up studies using a national sample cohort.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Follow-Up Studies; Humans; Hypogly | 2023 |
Editorial: Frontiers in diagnostic and therapeutic approaches in diabetic sensorimotor neuropathy.
Topics: Diabetes Mellitus; Diabetic Neuropathies; Humans; Metformin | 2023 |
The Influence of Sildenafil-Metformin Combination on Hyperalgesia and Biochemical Markers in Diabetic Neuropathy in Mice.
Topics: Animals; Biomarkers; Diabetes Mellitus; Diabetic Neuropathies; Hyperalgesia; Hypoglycemic Agents; In | 2023 |
Vitamin B12 status and peripheral neuropathy in patients with type 2 diabetes mellitus.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Humans; Hypoglyce | 2019 |
Stereological study on the numerical plasticity of myelinated fibers and oligodendrocytes in the rat spinal cord with painful diabetic neuropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Hypoglyc | 2020 |
Metformin Preserves Peripheral Nerve Damage with Comparable Effects to Alpha Lipoic Acid in Streptozotocin/High-Fat Diet Induced Diabetic Rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-Fat; Male; Metformin; Ra | 2020 |
Long-term metformin treatment and risk of peripheral neuropathy in older Veterans.
Topics: Aged; Alcoholism; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Humans; | 2020 |
The relationship between exacerbated diabetic peripheral neuropathy and metformin treatment in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Homocysteine; Humans; Male; Metformin; Met | 2021 |
Clinical Characteristics and Risk of Diabetic Complications in Data-Driven Clusters Among Type 2 Diabetes.
Topics: Adult; Aged; Blood Pressure; China; Cluster Analysis; Cross-Sectional Studies; Diabetes Mellitus, Ty | 2021 |
In This Issue of
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetic Neuropathies; Diabetic Retinopathy; Hum | 2018 |
Evaluation of the neonatal streptozotocin model of diabetes in rats: Evidence for a model of neuropathic pain.
Topics: Activating Transcription Factor 3; Amines; Animals; Animals, Newborn; Astrocytes; Cyclohexanecarboxy | 2018 |
Cardiac Autonomic Neuropathy as a Result of Mild Hypercaloric Challenge in Absence of Signs of Diabetes: Modulation by Antidiabetic Drugs.
Topics: Animals; Diabetic Cardiomyopathies; Diabetic Neuropathies; Dietary Fats; Energy Intake; Glucose Into | 2018 |
Metformin exacerbates and simvastatin attenuates myelin damage in high fat diet-fed C57BL/6 J mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diet, High-Fat; Hydroxymethylglutaryl-CoA | 2018 |
Metformin attenuates increase of synaptic number in the rat spinal dorsal horn with painful diabetic neuropathy induced by type 2 diabetes: a stereological study.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Hypoglycemic Agents; Male; Metformi | 2018 |
Prevalence of cardiovascular autonomic neuropathy and gastroparesis symptoms among patients with type 2 diabetes who attend a primary health care center.
Topics: Autonomic Nervous System; Blood Pressure; Cardiovascular System; Cross-Sectional Studies; Diabetes M | 2018 |
Preventive role of metformin on peripheral neuropathy induced by diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Hyperglycemia; Hypog | 2019 |
Cobalamin status and its relation with depression, cognition and neuropathy in patients with type 2 diabetes mellitus using metformin.
Topics: Adult; Aged; Cognition; Depressive Disorder; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Femal | 2015 |
Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments.
Topics: Animal Feed; Animals; Behavior, Animal; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neu | 2015 |
An inverse association between serum vitamin D levels with the presence and severity of impaired nerve conduction velocity and large fiber peripheral neuropathy in diabetic subjects.
Topics: Adult; Albuminuria; Case-Control Studies; Diabetic Neuropathies; Female; Humans; Hypertension; Linea | 2015 |
Metformin attenuates hyperalgesia and allodynia in rats with painful diabetic neuropathy induced by streptozotocin.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Enzy | 2015 |
Diabetic neuropathy is not associated with homocysteine, folate, vitamin B12 levels, and MTHFR C677T mutation in type 2 diabetic outpatients taking metformin.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Neuropa | 2016 |
Incidence, characteristics and impact of hypoglycaemia in patients receiving intensified treatment for inadequately controlled type 2 diabetes mellitus.
Topics: Aged; Amputation, Surgical; Angina, Stable; Asymptomatic Diseases; Blood Glucose; Depressive Disorde | 2016 |
Anti-inflammatory effect of AMPK signaling pathway in rat model of diabetic neuropathy.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dise | 2016 |
Vitamin B12 deficiency is associated with cardiovascular autonomic neuropathy in patients with type 2 diabetes.
Topics: Antihypertensive Agents; Autonomic Nervous System Diseases; Cardiovascular Diseases; Cohort Studies; | 2017 |
Role of treatment-modifying MTHFR677C>T and 1298A>C polymorphisms in metformin-treated Puerto Rican patients with type-2 diabetes mellitus and peripheral neuropathy.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dose-Response Relationship, Drug; Female; Hi | 2017 |
Pupillary autonomic neuropathy simulating partial Horner syndrome in diabetes mellitus and its reversal with control of blood glucose.
Topics: Adrenergic alpha-Agonists; Anisocoria; Blood Glucose; Clonidine; Diabetic Neuropathies; Female; Horn | 2008 |
Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.
Topics: Adult; Aged; Cohort Studies; Coronary Artery Bypass; Coronary Artery Disease; Cross-Sectional Studie | 2009 |
Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy.
Topics: Aged; Case-Control Studies; Chromatography, High Pressure Liquid; Diabetic Neuropathies; Electrophys | 2010 |
The role of combination therapy in type 2 diabetes in the post-ACCORD era.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; D | 2012 |
Evaluation of vitamin B12 monitoring in a veteran population on long-term, high-dose metformin therapy.
Topics: Anemia; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Monitoring; Humans; Hypoglycemic Agen | 2012 |
Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cells, Cultured; Cerebral Cortex; Cyclosporin | 2008 |
A 64-year-old man with adult-onset diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Glucose Self-Monitoring; Carotid Stenosis; Decision | 1996 |
Metformin as an adjunctive therapy for NIDDM.
Topics: Adult; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabe | 1996 |
The prevalence of chronic diarrhea among diabetic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Autonomic Nervous System Dis | 1999 |
Contra-indications to metformin therapy are largely disregarded.
Topics: Adult; Aged; Aged, 80 and over; Contraindications; Coronary Disease; Cross-Sectional Studies; Diabet | 1999 |
Glycaemic and blood pressure controls achieved in a cohort of 318 patients with type 2 diabetes.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; A | 1999 |
Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models.
Topics: Animals; Diabetic Neuropathies; Guanidines; Hydroxylamines; Hypoglycemic Agents; Insulin Resistance; | 2002 |